Search - tctmd.com

Displaying 241 - 260 of 2476

Sort: Relevancy | Date

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Strengths and Weaknesses of CMR for Quantification of MR

Presenter: Paul A. Grayburn, Patrizio Lancellotti, Stamatios Lerakis

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Neil E. Moat

October 30, 2016

Presentation TCT 2016

Prognostic and Treatment Decision Implications of Exercise Induced Mitral Regurgitation

Presenter: Paul A. Grayburn, Patrizio Lancellotti

October 30, 2016

Presentation TCT 2016

The TAVR Development Journey: Lessons Learned and Drivers of Success

Presenter: John G. Webb, Ajit Yoganathan

October 30, 2016

Presentation TCT 2016

Echo Quantification of MR Severity: Classification and Common Pitfalls

Presenter: Paul A. Grayburn, Patrizio Lancellotti

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies II: Updates From SURTAVI

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Martin B. Leon

October 30, 2016

Presentation TCT 2016

Transcatheter Mitral Replacement Devices: An Update from the International Organization for Standardization (ISO) Cardiac Valves Committee

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu, Aaron Chalekian

October 30, 2016

Presentation TCT 2016

Whats New and What's Controversial in the US and EU Guidelines?

Presenter: Ted Feldman, Allan Schwartz, Catherine M. Otto

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, John G. Webb

October 30, 2016

Presentation TCT 2016

Medical Therapy, Revascularization, and CRT for Functional Mitral Regurgitation: Despite Class I Guidelines, Are the Benefits Substantial?

Presenter: Ted Feldman, Allan Schwartz, JoAnn Lindenfeld

October 30, 2016

Presentation TCT 2016

Animal Testing: Real-World Experiences and Translational Challenges

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu

October 30, 2016

Presentation TCT 2016

Flash Debate: Point Guidelines Should Remain the Standard for Clinical Practice!

Presenter: Patrick T. O'Gara, Alec S. Vahanian

October 30, 2016

Presentation TCT 2016

Animal Testing: FDA Expectations

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu, Natalie Miller

October 30, 2016

Presentation TCT 2016

Epidemiology and Treatment of Primary and Secondary Mitral Regurgitation: Global Perspectives

Presenter: Ted Feldman, Allan Schwartz, Ralph Stephan von Bardeleben

October 30, 2016

Presentation TCT 2016

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Catherine M. Otto

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu

October 30, 2016

Presentation TCT 2016

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Samir R. Kapadia

October 30, 2016

Advertisement

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Strengths and Weaknesses of CMR for Quantification of MR

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Prognostic and Treatment Decision Implications of Exercise Induced Mitral Regurgitation

The TAVR Development Journey: Lessons Learned and Drivers of Success

Echo Quantification of MR Severity: Classification and Common Pitfalls

Intermediate-Risk Studies II: Updates From SURTAVI

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Transcatheter Mitral Replacement Devices: An Update from the International Organization for Standardization (ISO) Cardiac Valves Committee

Whats New and What's Controversial in the US and EU Guidelines?

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Medical Therapy, Revascularization, and CRT for Functional Mitral Regurgitation: Despite Class I Guidelines, Are the Benefits Substantial?

Animal Testing: Real-World Experiences and Translational Challenges

Flash Debate: Point Guidelines Should Remain the Standard for Clinical Practice!

Animal Testing: FDA Expectations

Epidemiology and Treatment of Primary and Secondary Mitral Regurgitation: Global Perspectives

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

FDA Perspectives

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content